A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

被引:1
|
作者
Assaf, Chalid [1 ,2 ]
Illidge, Timothy M. [3 ]
Waser, Nathalie [4 ]
He, Mary [4 ]
Li, Tina [4 ]
Zomas, Athanasios [5 ]
Bent-Ennakhil, Nawal [5 ]
Little, Meredith [6 ,10 ]
Ortiz-Romero, Pablo L. [7 ]
Pimpinelli, Nicola [8 ]
Dalal, Mehul [6 ]
Bagot, Martine [9 ]
机构
[1] Helios Klinikum Krefeld, Dept Dermatol, Lutherpl 40, D-47805 Krefeld, Germany
[2] Med Sch Hamburg, Inst Mol Med, D-20457 Hamburg, Germany
[3] Univ Manchester, Christie Hosp, Manchester NIHR BRC Ctr, Manchester M20 4BX, England
[4] ICON Plc, 3455 North Serv Rd,Unit 400, Burlington, ON L7N 3G2, Canada
[5] Takeda Pharmaceut Int AG, Thurgauerstr 130, CH-8152 Zurich, Switzerland
[6] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA 02421 USA
[7] Univ Complutense, Hosp Octubre 12, Inst I 12, Med Sch,Dept Dermatol,CIBERONC, Madrid 28041, Spain
[8] Univ Florence, Hosp P Palagi, Med Sch, Sect Dermatol,Dept Hlth Sci, Viale Michelangiolo 41, I-50125 Florence, Italy
[9] Univ Paris Cite, St Louis Hosp, 1 Ave Claude Vellefaux, F-75010 Paris, France
[10] Agios Pharmaceut, Cambridge, MA 02129 USA
关键词
mycosis fungoides; relapsed/refractory; treatment patterns; Europe; real-world data; observational study; overall survival; progression-free survival; HEMATOPOIETIC-CELL TRANSPLANTATION; EORTC CONSENSUS RECOMMENDATIONS; PRIMARY CUTANEOUS LYMPHOMAS; SEZARY-SYNDROME; INTERNATIONAL-SOCIETY; BRENTUXIMAB VEDOTIN; ORGANIZATION; GUIDELINES; DIAGNOSIS;
D O I
10.3390/cancers15235669
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Here, we report real-world treatment patterns and the overall survival of 104 patients with relapsing/refractory (R/R) MF who had received first-line therapy between 1984 and 2016. Our study found that second- and third-line therapies for R/RMF were heterogeneous, including systemic therapies, radiotherapy and topical therapies. More than two-thirds of patients at second- and third-line treatment received chemotherapy, and we observed that the median overall survival was longer with non-chemotherapy (not reached) vs. chemotherapy (6.5 years) treatment, suggesting that non-chemotherapy options may be more beneficial to patients.Abstract (1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lymphoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort study analyzed patient records (1984-2016) from 27 clinical sites in Europe. Outcomes included treatments received, response to first-, second- and third-line treatment, overall survival (OS) and progression-free survival (PFS). (3) Results: Of 104 patients with MF, 100 received second-line and 61 received third-line therapy. The median (range) times from the start of first-line therapy to the first R/R MF and from the first to the second R/R MF were 11.2 (0.3-166.5) and 13.5 (0.0-174.6) months, respectively. Second-and third-line treatment options varied and comprised systemic therapies (85% and 79% of patients, respectively), radiotherapy (32% and 34%, respectively) and topical therapies (48% and 36%, respectively). The median (95% confidence interval [CI]) OS from the diagnosis of the first R/R MF was 11.5 (6.5-not reached [NR]) years and was higher with non-chemotherapy (NR) versus chemotherapy (6.5 years); the estimated median PFS (95% CI) from the time of the first R/R MF was 1.3 (1.0-2.1) years. (4) Conclusions: High rates of R/R disease were observed after second- and third-line treatments in this real-world cohort, with longer median OS in patients receiving non-chemotherapy treatment versus chemotherapy. Following the standard management of MF and using recently approved targeted therapies can help improve patient outcomes in advanced-stage MF.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] REAL WORLD TREATMENT PATTERNS OF PCSK9 INHIBITORS AMONG PATIENTS WITH DYSLIPIDEMIA IN GERMANY, SPAIN, AND UNITED KINGDOM
    Tai, M.
    Shepherd, J.
    Bailey, H.
    Hatz, M.
    Tapias, Campos, I
    Catterick, D.
    Worth, G.
    VALUE IN HEALTH, 2017, 20 (09) : A627 - A627
  • [22] IMPACT ON HEALTHCARE RESOURCE UTILIZATION AND INDIRECT COSTS AMONG INDIVIDUALS WITH MIGRAINE AND PREVENTIVE TREATMENT FAILURE IN FRANCE, GERMANY, ITALY, SPAIN AND UNITED KINGDOM
    Buse, D. C.
    Pozo-Rosich, P.
    Reuter, U.
    Balkaran, B. L.
    Way, N.
    Jauregui, A.
    Gandhi, P.
    Parikh, M.
    Dupont-Benjamin, L.
    VALUE IN HEALTH, 2022, 25 (12) : S92 - S92
  • [23] Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European countries (United Kingdom, France, Germany, Italy, Spain)
    Bailey, A.
    Perera, S.
    d'Estrube, T.
    Ribbands, A.
    Luke, E.
    Wang, P. Feng
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S835 - S836
  • [24] TREATMENT PATTERNS FOR PARKINSON'S DISEASE: REAL-WORLD EVIDENCE FROM THE EU5 (FRANCE, GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM)
    Sung, A. H.
    Kulkarni, A.
    Svarvar, P.
    VALUE IN HEALTH, 2013, 16 (07) : A630 - A630
  • [25] Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom
    Tai, Ming-Hui
    Shepherd, Jason
    Bailey, Hollie
    Williams, Nathan
    Hatz, Maximilian
    Tapias, Ignasi Campos
    Catterick, David
    Worth, Gavin
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 829 - 835
  • [26] Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National Healthcare database (SNDS)
    Touzeau, Cyrille
    Quignot, Nadia
    Meng, Jie
    Jiang, Heng
    Khachatryan, Artak
    Singh, Moushmi
    Taieb, Vanessa
    Chauny, Jean-Vannak
    Desamericq, Gaelle
    ANNALS OF HEMATOLOGY, 2021, 100 (07) : 1825 - 1836
  • [27] Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)
    Cyrille Touzeau
    Nadia Quignot
    Jie Meng
    Heng Jiang
    Artak Khachatryan
    Moushmi Singh
    Vanessa Taieb
    Jean-Vannak Chauny
    Gaëlle Désaméricq
    Annals of Hematology, 2021, 100 : 1825 - 1836
  • [28] Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study
    Szabo, Shelagh M.
    Hirji, Ishan
    Johnston, Karissa M.
    Juarez-Garcia, Ariadna
    Connors, Joseph M.
    PLOS ONE, 2017, 12 (10):
  • [29] Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
    Andrea Leith
    Jeri Kim
    Amanda Ribbands
    Emily Clayton
    Lingfeng Yang
    Sameer R. Ghate
    Advances in Therapy, 2022, 39 : 2236 - 2255
  • [30] Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan
    Leith, Andrea
    Kim, Jeri
    Ribbands, Amanda
    Clayton, Emily
    Yang, Lingfeng
    Ghate, Sameer R.
    ADVANCES IN THERAPY, 2022, 39 (05) : 2236 - 2255